El Salvador: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in El Salvador

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: El Salvador: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

Subscribe to access the full database, or Try a Trial
Tradename	Ingredient	Estimated Entry Opportunity Date
OLYSIO	simeprevir sodium	2025-07-29
NATAZIA	dienogest; estradiol valerate	2024-04-20
YONDELIS	trabectedin	2024-10-29
>Tradename	>Ingredient	>Estimated Entry Opportunity Date

Details: El Salvador: These 2 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

When can OLYSIO (simeprevir sodium) generic drug versions launch?

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: El Salvador Patent 2,008,002,642

OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.

This drug has one hundred and thirty-nine patent family members in forty-three countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 20, 2024
Generic Entry Controlled by: El Salvador Patent 2,006,002,090

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

When can YONDELIS (trabectedin) generic drug versions launch?

Generic name: trabectedin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 29, 2024
Generic Entry Controlled by: El Salvador Patent 2,006,002,283

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.